Blog

The more I read about patient centricity, the more I get the eerie feeling that there is something wrong, something missing. At first glance the concept is very clear, the strategy and tactics are right and the tools put to use all have an added value. But it still doesn’t feel quite right to me. So what is it? Being responsible for business development, I fully understand why the...

Lees verder

When reading about patient centricity one might get the impressions that technology will make it all happen. A lot of money is spent on portal solutions to make trial information more accessible for patients, and on mobile apps that will make it easier for patients to share the information the industry needs from them. But looking at these solutions the question pops to mind how all of this will...

Lees verder

Reasons for Change It has all been said before: Over 95% of the clinical studies fail to meet their original time lines and budgets[1] and that one day of delay could cost a sponsor $1.6 million on averaged lost revenue.[2] Between 2006 and 2016 the global spending on drug development will grow from $108 billion to over $148 billion.[3] Clinical trials account for 45% to 75% of this cost[4] and...

Lees verder

A very interesting read, shared by our BEAMER colleagues at Pfizer. It identifies not only risk factors for adherence in three disease areas, but also the potentially most effective interventions to improve adherence. The conclusions of this 2022 publication are fully in line with our rationale in 2017 to start developing our Adherence Risk Management (ARM) services for clinical...

Lees verder